Adhera Therapeutics, Inc. (ATRX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Adhera Therapeutics, Inc. (ATRX) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Adhera Therapeutics, Inc. (ATRX) Resumen de Asistencia Médica y Tuberías
Adhera Therapeutics, Inc., formerly Marina Biotech, focuses on drug discovery and development within the biotechnology sector. Based in Baton Rouge, Louisiana, the company operates with a small team, navigating the competitive landscape of pharmaceutical innovation with a focus on identifying and advancing novel therapeutic candidates.
Tesis de Inversión
Investing in Adhera Therapeutics presents a high-risk, high-reward scenario typical of early-stage biotechnology companies. With a market capitalization of $0.00 billion and a negative price-to-earnings ratio, the company's valuation is speculative and tied to the potential success of its drug development pipeline. A key value driver is the advancement of drug candidates through clinical trials, which could trigger significant stock appreciation. Upcoming catalysts include potential partnerships, grant funding, and positive clinical trial results. However, the company faces substantial risks, including limited financial resources, regulatory hurdles, and competition from larger pharmaceutical companies. The high beta of 3.73 indicates significant volatility, making this investment suitable only for risk-tolerant investors.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.00 billion, reflecting its status as a micro-cap company.
- Negative price-to-earnings ratio, indicating the company is currently not profitable.
- Beta of 3.73, suggesting high volatility compared to the overall market.
- Focus on drug discovery and development, positioning it within the high-growth biotechnology sector.
- Operates with a small team of 2 employees, indicating a lean operational structure.
Competidores y Pares
Fortalezas
- Focus on drug discovery and development
- Small, agile team
- Potential for breakthrough therapies
- Strategic location in Baton Rouge, Louisiana
Debilidades
- Limited financial resources
- Small team size
- Dependence on external funding
- Lack of commercialized products
Catalizadores
- Upcoming: Potential partnerships with larger pharmaceutical companies to fund and develop drug candidates.
- Upcoming: Grant funding from government agencies or non-profit organizations to support research and development.
- Upcoming: Positive results from preclinical studies of drug candidates.
- Ongoing: Advancement of drug candidates through clinical trials.
- Ongoing: Expansion into new therapeutic areas to diversify the pipeline.
Riesgos
- Potential: Limited financial resources to fund drug development programs.
- Potential: Competition from larger, better-funded pharmaceutical companies.
- Potential: Regulatory hurdles and approval delays for drug candidates.
- Ongoing: Clinical trial failures and setbacks.
- Ongoing: Dependence on external funding and strategic partnerships.
Oportunidades de crecimiento
- Expansion into New Therapeutic Areas: Adhera Therapeutics can explore new therapeutic areas beyond its current focus to diversify its pipeline and reduce risk. The global market for pharmaceuticals is projected to reach $1.5 trillion by 2026. Entering new areas like oncology or immunology could open up significant revenue streams. This expansion would require strategic partnerships and additional funding, with potential impact visible within 3-5 years.
- Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions can provide Adhera Therapeutics with access to funding, expertise, and resources. The value of biotech collaborations reached $150 billion in 2025. A successful partnership could accelerate drug development and increase the company's visibility. Expect potential partnership announcements within the next 1-2 years.
- Securing Grant Funding: Pursuing grant funding from government agencies and non-profit organizations can provide non-dilutive capital to support research and development efforts. The National Institutes of Health (NIH) awards billions of dollars in grants annually. Securing even a small grant could significantly extend the company's runway. Grant applications and approvals typically take 6-12 months.
- Advancement of Drug Candidates Through Clinical Trials: Successfully advancing drug candidates through clinical trials is critical for creating value. Positive clinical trial results can lead to regulatory approval and commercialization. The cost of bringing a drug to market can exceed $2 billion. Each phase of clinical trials represents a major milestone and potential catalyst for the stock. Expect incremental progress updates on clinical trials every 6-18 months.
- Acquisition by a Larger Pharmaceutical Company: Given its focus on drug discovery, Adhera Therapeutics could become an acquisition target for a larger pharmaceutical company seeking to expand its pipeline. The value of biotech acquisitions reached $200 billion in 2025. A successful acquisition would provide a significant return for investors. The likelihood of an acquisition depends on the progress of its drug candidates and the overall market environment. Timing is unpredictable, but potential within 2-5 years.
Oportunidades
- Strategic partnerships with larger pharmaceutical companies
- Grant funding from government agencies
- Advancement of drug candidates through clinical trials
- Acquisition by a larger pharmaceutical company
Amenazas
- Competition from larger, better-funded companies
- Regulatory hurdles and approval delays
- Clinical trial failures
- Patent expirations
Ventajas competitivas
- Proprietary drug discovery platform.
- Intellectual property protection for its drug candidates.
- Expertise in specific therapeutic areas.
Acerca de ATRX
Adhera Therapeutics, Inc., headquartered in Baton Rouge, Louisiana, is a biotechnology company engaged in the discovery and development of pharmaceutical products. Originally established as Marina Biotech, Inc., the company underwent a name change in October 2018 to reflect its evolving strategic direction. Adhera Therapeutics operates with a lean structure, currently managing its research and development efforts with a team of two employees. The company's primary focus is on identifying and developing novel drug candidates, aiming to address unmet medical needs. While specific details on their current pipeline are not available, the company's history suggests an interest in innovative therapeutic approaches. Adhera Therapeutics navigates the competitive biotechnology landscape, seeking to advance its drug development programs through preclinical and clinical stages.
Qué hacen
- Focuses on the discovery of new drugs.
- Engages in the development of pharmaceutical products.
- Aims to address unmet medical needs through innovative therapies.
- Conducts preclinical research to identify promising drug candidates.
- Potentially conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Seeks partnerships and collaborations to advance its drug development programs.
Modelo de Negocio
- Focuses on discovering and developing drugs.
- Seeks to monetize its drug candidates through partnerships or acquisitions.
- May generate revenue through licensing agreements or milestone payments.
Contexto de la Industria
Adhera Therapeutics operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The industry is driven by innovation, with companies constantly seeking to develop novel therapies for unmet medical needs. The competitive landscape includes established pharmaceutical giants, as well as numerous smaller biotechnology firms. Adhera Therapeutics, with its small size and focus on drug discovery, faces the challenge of competing with larger, better-funded companies. Success in this industry requires strong intellectual property, efficient clinical trial execution, and strategic partnerships.
Clientes Clave
- Pharmaceutical companies seeking to expand their drug pipelines.
- Patients who may benefit from new therapies developed by the company.
- Healthcare providers who may prescribe the company's drugs.
Finanzas
Gráfico e información
Precio de la acción de Adhera Therapeutics, Inc. (ATRX): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ATRX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ATRX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ATRX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Andrew Albert Kucharchuk
CEO
Andrew Albert Kucharchuk serves as the CEO of Adhera Therapeutics, Inc. His background and experience prior to joining Adhera Therapeutics are not detailed in the provided data. As the managing member of a small team, Kucharchuk is responsible for overseeing the company's strategic direction and day-to-day operations. His leadership is critical to navigating the challenges of drug discovery and development within the biotechnology sector.
Historial: Given the limited information available, it is difficult to assess Andrew Albert Kucharchuk's track record at Adhera Therapeutics. The company's small size and early stage of development suggest that Kucharchuk's primary focus has been on securing funding, advancing drug candidates, and building strategic partnerships. Key milestones under his leadership would include successful preclinical studies, IND filings, and positive clinical trial results.
Información del mercado OTC de ATRX
The OTC Other tier represents the lowest tier of the OTC market, indicating that Adhera Therapeutics may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight. This contrasts sharply with companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements and reporting obligations.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements (if available)
- Research the background of the company's management team
- Assess the company's business model and competitive landscape
- Review any available news articles or press releases
- Consult with a financial advisor
- Understand the risks associated with investing in OTC stocks
- Confirm the company's registration status with the SEC (if applicable)
- Company's history of operations (formerly Marina Biotech)
- Focus on drug discovery and development
- Presence of a CEO and management team
- Company filings with OTC Markets (if available)
- Any patents or intellectual property owned by the company
Lo Que los Inversores Preguntan Sobre Adhera Therapeutics, Inc. (ATRX)
¿Cuáles son los factores clave para evaluar ATRX?
Adhera Therapeutics, Inc. (ATRX) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Focus on drug discovery and development. Riesgo principal a monitorear: Potential: Limited financial resources to fund drug development programs.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ATRX?
ATRX actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ATRX?
Los precios de ATRX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ATRX?
La cobertura de analistas para ATRX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ATRX?
Las categorías de riesgo para ATRX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Limited financial resources to fund drug development programs.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ATRX?
La relación P/E para ATRX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ATRX sobrevalorada o infravalorada?
Determinar si Adhera Therapeutics, Inc. (ATRX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ATRX?
Adhera Therapeutics, Inc. (ATRX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available on the company's current pipeline and financial performance.
- OTC listing indicates higher risk and lower transparency.